Avelumab

Evidence Level: L5

Predicted Indications: 9

Avelumab

Pharmacist Assessment Report

One-Sentence Summary

Avelumab was originally used to treat cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). The TxGNN model predicts it may be effective for human herpesvirus 8-related tumor, but no clinical trials or publications were found in the data compiled for this report, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Cutaneous neuroendocrine carcinoma
Predicted New Indication	Human herpesvirus 8-related tumor
TxGNN Prediction Score	0.9997
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Avelumab is an antibody that blocks PD-L1, a checkpoint inhibitor, and its use in cutaneous neuroendocrine carcinoma is established. Mechanistically, it may be applicable to human herpesvirus 8-related tumors. This reasoning comes from general knowledge, not from the supplied data.

Tumors driven by herpesvirus 8 (for example, Kaposi sarcoma) can express PD-L1. Blocking PD-L1 could restore T-cell antitumour activity. This link is plausible but has not been verified against the record.

Other predictions for this drug are also listed below. They are all supported by model output only:

Urothelial sites (prostatic urethra urothelial carcinoma, score 0.9992; kidney pelvis sarcomatoid transitional cell carcinoma, score 0.9991) have the most plausible rationale, because avelumab is known to be used in advanced urothelial carcinoma. These are flagged as research questions, and checking whether existing urothelial trial populations included these subsites could raise the evidence level.
Rare neuroendocrine or cutaneous tumors (middle ear neuroendocrine tumor, malignant cutaneous granular cell skin tumor, ectomesenchymoma) may reflect similarity to the original indication. PD-L1 relevance is unestablished.
Congenital immunodeficiencies (adenosine deaminase deficiency, reticular dysgenesis, immunoerythromyeloid hypoplasia, non-severe combined immunodeficiency) have no credible mechanistic link. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Immune activation in these settings is a theoretical safety concern.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02469723	BAVENCIO	Not specified	Not specified

Safety Considerations

Drug Interactions: Three Major-level interactions were identified, all with immunomodulatory agents:
- Lenalidomide
- Pomalidomide
- Thalidomide

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high (0.9997), but no clinical trials or literature support the prediction, so the evidence level is L5. The mechanistic rationale for the herpesvirus 8-related tumor comes from general knowledge and cannot be checked against the data compiled for this report.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data (for example, from DrugBank)
Targeted literature and trial searches for HHV-8-related tumors, such as Kaposi sarcoma, including PD-L1 expression data
For the urothelial subsite predictions, a review of whether existing urothelial carcinoma trials included these subsites
Review of the three Major drug interactions (lenalidomide, pomalidomide, thalidomide) before any combination use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.